Thomas Hope and Prashant Jolepalem Chosen as Recipients of the 2016 Henkin Fellowship

SNMMI and the Education and Research Foundation for Nuclear Medicine and Molecular Imaging are pleased to announce that Thomas Hope, MD, and Prashant Jolepalem, MD, CCD, are the recipients of the 2016 Robert E. Henkin Government Relations Fellowship. Each year, the recipients come to Washington, DC, and spend a week with SNMMI staff, visiting Congress, federal agencies and other medical societies. Throughout the week, the Fellows learn, first-hand, how the federal legislative, and regulatory process impacts nuclear medicine and molecular imaging. The program is designed for young professionals defined as residents or fellows (physicians, scientists or technologists who have completed their training within the last 10 years).

Dr. Jolepalem currently serves in a dual role as a Nuclear Medicine Physician at the William Beaumont Health System in Royal Oak, Michigan, and the Westchester PET and Medical Imaging facility in Hawthorne, NY. He received his medical degree from St. Matthew’s University School of Medicine in 2009. His areas of expertise include positron emission tomography (PET), computerized tomography (CT), and single-photon emission computed tomography CT (SPECT-CT) scans. Dr. Jolepalem wishes to use the Henkin Fellowship to become a “physician statesman” to create a more involved physician group that can advocate for more sustainable and beneficial healthcare policies.

Dr. Hope currently serves as an Assistant Professor at the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. While teaching, Dr. Hope has spent the past two years testing DOTA-TOC and Ga-68 HBED-CC PSMA through the U.S. Food and Drug Administration (FDA) Investigation New Drug (IND) pathway. His team performed over 150 studies using DOTA-TOC and is collaborating with the University of Iowa to receive full FDA approval for this agent. Through his work with the FDA, Dr. Hope was exposed to the complexities involved in getting approval for radiotracers. Dr. Hope wishes to use the Henkin Fellowship to deepen his understanding of this process to increase patient access to these radiotracers.

This fellowship would not be possible without the generous contributions made by Dr. Robert E. Henkin. Dr. Henkin’s hard work and dedication to nuclear medicine and molecular imaging have been invaluable to SNMMI.